Treatment: CPAP, Alternatives, and the Data on Each
Continuous positive airway pressure (CPAP) therapy — delivering constant pressurized air through a mask to mechanically splint the airway open — remains the most effective treatment for moderate-to-severe OSA. Properly titrated CPAP eliminates apneic events in essentially all cases, normalizes blood oxygen, restores sleep architecture, and produces measurable reductions in blood pressure (particularly in hypertensive patients), daytime sleepiness, cognitive function, and quality of life. The challenge is adherence: approximately 50% of patients use CPAP for fewer than 4 hours per night — the threshold below which cardiovascular benefits become inconsistent. Modern CPAP devices with heated humidification, auto-titrating algorithms, and detailed compliance data have substantially improved adherence rates compared to earlier technology.
Mandibular advancement devices (MADs) — custom-fitted oral appliances that bring the lower jaw and tongue forward, increasing posterior airway space — are effective for mild-to-moderate OSA and increasingly for some severe cases. Meta-analyses show MADs reduce AHI by an average of 50%, compared to CPAP’s near-complete elimination, but MADs achieve substantially better adherence because they are comfortable, quiet, and require no power source. Multiple head-to-head randomized trials show that despite CPAP’s superior efficacy in laboratory settings, long-term health outcomes (blood pressure reduction, quality of life, daytime function) are equivalent or sometimes better with MADs because patients actually wear them. The choice between CPAP and MAD should consider the patient’s disease severity, anatomy, and likelihood of adherence rather than efficacy data alone.
Positional therapy is an underused and undervalued treatment option for positional OSA — cases in which AHI in the supine position is at least twice the non-supine AHI. Approximately 60% of OSA patients have positional OSA, and in many, avoiding supine sleep normalizes their AHI to the same degree as CPAP. Traditional positional therapy (sewing a tennis ball into the back of a pajama shirt) has limited efficacy, but modern vibrotactile feedback devices that vibrate when supine sleeping is detected achieve significantly better results — the NightBalance device demonstrated AHI reductions of 50%+ with superior adherence compared to CPAP in a large randomized trial.
Surgical options have evolved significantly beyond traditional uvulopalatopharyngoplasty (UPPP), which had inconsistent results and no durability. Hypoglossal nerve stimulation (Inspire therapy) — an implanted device that synchronizes tongue muscle activation with breathing efforts using a chest-wall sensor — produces AHI reductions of 68% at 12 months with 88% of patients achieving therapeutic response, and shows durable benefit at 5-year follow-up. This treatment is indicated for CPAP-intolerant patients with moderate-to-severe OSA, AHI 15-65, and specific anatomical criteria. Weight loss produces dramatic improvements in sleep apnea severity: a 10% weight reduction reduces AHI by approximately 26%, and bariatric surgery achieves remission of moderate-to-severe OSA in 40-80% of patients with obesity.